Vonoprazan is a first-in-class potassium-competitive acid blocker (P-CAB) used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome.… Read more








![Chemical structure of (6-Amino-8-((2,6-dimethylbenzyl)(hydroxy)amino)-2-methylimidazo[1,2-a]pyridin-3-yl)methanol](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F6-Amino-8-26-dimethylbenzylhydroxyamino-2-methylimidazo12-apyridin-3-ylmethanol.png&w=3840&q=75)
![Chemical structure of (8-((2,6-Dimethylbenzyl)amino)-6-(hydroxyamino)-2-methylimidazo[1,2-a]pyridin-3-yl)methanol](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F8-26-Dimethylbenzylamino-6-hydroxyamino-2-methylimidazo12-apyridin-3-ylmethanol.png&w=3840&q=75)








































Vonoprazan is a first-in-class potassium-competitive acid blocker (P-CAB) used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome. By competitively inhibiting the H+/K+-ATPase enzyme in gastric parietal cells, it effectively suppresses gastric acid secretion. This category provides a comprehensive selection of reference standards for Vonoprazan, including the active pharmaceutical ingredient, its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds. Pharmaceutical laboratories utilize these high-quality materials for critical analytical testing, including impurity profiling, method validation, and quality control. These standards are essential for identifying process-related impurities or degradation products that may form during synthesis or storage. By supporting accurate quantification and characterization, these reference compounds help ensure the potency, safety, and regulatory compliance of drug products throughout the development and manufacturing lifecycle.